

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

THE PRESENTATION OF GeminiOne® TRANSCATHETER EDGE-TO-EDGE REPAIR (“TEER”) SYSTEM AND MonarQ™ TRANSCATHETER TRICUSPID VALVE REPLACEMENT (“TTVR”) SYSTEM AT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (“TCT”) 2023 CONFERENCE IN THE UNITED STATES

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that GeminiOne® TEER system and MonarQ™ TTVR system were presented at the TCT 2023 conference in the United States.

Dr. Saibal Kar, M.D., program director of cardiology at Los Robles Regional Medical Center and physician director of interventional cardiology at HCA Healthcare, presented the GeminiOne® TEER technology and the early clinical experiences of the device during the mitral TEER session. GeminiOne® is a novel TEER device and is currently investigated under a pivotal clinical study in China, led by Academician Shengshou Hu and Professor Xiangbin Pan from Fuwai Hospital of Chinese Academy of Medical Sciences. The early feasibility study in the United States is expected to commence in 2024.

Dr. Arshad Quadri, M.D., cardiac surgeon, co-founder, executive chairman and chief medical officer of inQB8 Medical Technologies, LLC (“**inQB8**”) shared the experience from animal studies and early First-in-Man (“**FIM**”) clinical trial of MonarQ™ during the tricuspid valve diseases and intervention sessions. MonarQ™ is a novel TTVR device jointly developed by the Group and inQB8. FIM clinical trial is currently ongoing and we are planning for early feasibility study in the United States.

TCT 2023 conference was held in San Francisco from October 23, 2023 to October 26, 2023. TCT conference is the annual scientific symposium of the Cardiovascular Research Foundation.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET GeminiOne® TEER SYSTEM AND MonarQ™ TTVR SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, October 27, 2023

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Dr. Zhiyun YU, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.